HiberCell, Inc. has acquired the Imprime PGG program from Biothera Pharmaceuticals, Inc.
This website will deactivate on August 31. To learn more visit HiberCell.com

Monthly Archives: December 2015

Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck’s Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer

EAGAN, MN — December 10, 2015 — Biothera Pharmaceutical Inc., today announced plans for a Phase 1b/2 clinical study in non-small lung cancer (NSCLC) patients to evaluate the ability of Biothera’s Imprime PGG to enhance responses to pembrolizumab (Keytruda®), the anti-PD-1 antibody from Merck (NYSE:MRK), known as MSD outside the United States and Canada. Merck will provide funding and clinical supplies of pembrolizumab for the...

Read More